Genus plc (LSE: GNS)
Health Care · Biotechnology · GB
£22.72
-0.35% today · -13.6% 1Y
Genus plc (LSE: GNS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.02B and employs 3,190 people.
Over the last twelve months the share price has lost 13.6%, trading between 19.43 and 32.20.
Tweenvest scores Genus plc across four factors: quality 79/100, value 69/100, growth 59/100, dividend 59/100. Its strongest factor is quality.
GNS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.02B
- Revenue (TTM)
- $873.16M
- P/E
- 5.36
- EPS
- 4.25
- Dividend yield
- 1.58%
- Beta (5Y)
- 0.91
- 52-week high
- £32.20
- 52-week low
- £19.43
- Avg volume (3M)
- —
- Shares outstanding
- 66.92M
- Employees
- 3,190
- Next earnings
- —
About Genus plc
Genus plc is a global animal genetics company with operations spanning North America, Latin America, the UK, continental Europe, the Middle East, Russia, Africa, and Asia. The business is divided into three key segments: Genus PIC, Genus ABS, and Genus Research and Development. Under its PIC brand, the company provides breeding stock, including sows, boars, and semen, to develop pigs with specific characteristics optimized for pork production. Similarly, for cattle, its ABS, Genus, and Bovec brands offer bull semen and embryos designed to produce calves with advantageous traits for either milk or beef output. Farmers also benefit from a range of specialized technical services, such as semen sexing and reproductive solutions. Genus plc is also strategically collaborating with Beijing Capital Agribusiness Co. Ltd on the research, development, and regulatory approval of porcine reproductive and respiratory syndrome virus (PRRSV)-resistant pigs in China. The company was established in 1994 and is based in Basingstoke, United Kingdom.
- ISIN
- GB0002074580
- Founded
- 1994
- Listed since
- Jul 6, 2000
- Exchange
- London Stock Exchange
- Currency
- GBP
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AlvotechNasdaqGM: ALVO | $2.06B | $5.52 | -4.58% |
| Vericel CorporationNasdaqGM: VCEL | $2.05B | $40.28 | +0.45% |
| Nanjing Vazyme Biotech Co., LtdSHSE: 688105 | $2.05B | CN¥26.60 | -2.35% |
| Wuhan Healthgen Biotechnology Corp.SHSE: 688765 | $2.02B | CN¥37.86 | -4.97% |
| Palvella Therapeutics, Inc.NasdaqGM: PVLA | $2.00B | $132.89 | -4.24% |
| ABL Bio Inc.KOSDAQ: A298380 | $2.00B | ₩48,000.00 | -6.61% |
| ADARx Pharmaceuticals, Inc.NasdaqGS: ADRX | $1.99B | $17.78 | 0.00% |
| OliX Pharmaceuticals, IncKOSDAQ: A226950 | $1.99B | ₩117,300.00 | +0.43% |
Figures last refreshed Oct 11, 2026.